Maximal androgen blockade increases fracture risk by odds ratio 1.5 to 2.4 compared to ADT
Managing Bone Health Risks for Men Receiving Advanced Prostate Cancer Treatments
This meta-analysis of 16162 patients with prostate cancer found that maximal androgen blockade (MAB) significantly increases the risk of fra…
New research shows that combining certain hormone therapies for prostate cancer can increase fracture risks, making bone protection very imp…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Lu-PSMA-617 combined with ADT and ARPI reduced radiographic progression risk by 28%
New Treatment Options for Men with Advanced Prostate Cancer
This Phase 3 randomized controlled trial of 1144 patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate …
A large study shows that adding a specific radioactive treatment to standard hormone therapy can help slow cancer growth.